...
首页> 外文期刊>Veterinary and Comparative Oncology >Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.
【24h】

Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.

机译:评估15周CHOP方案治疗犬多中心淋巴瘤。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Dose intense CHOP protocols have been shown to improve outcome for people with non-Hodgkin's lymphoma, but evaluation of dose intense CHOP protocols for canine lymphoma is currently limited. The hypothesis of this retrospective study was that a 15-week dose intense CHOP protocol would have shorter treatment duration with similar efficacy to other doxorubicin-based multidrug protocols. Thirty-one client owned dogs with multicentric lymphoma were treated with a 15-week CHOP chemotherapy protocol with an overall response rate of 100% and a median progression-free interval (PFI) of 140 days [95% confidence interval (CI) 91-335 days]. Dogs that had two or more treatment delays had significantly prolonged PFI and overall survival in multivariate analysis. Dose intensity did not correlate with patient outcome. Dogs experiencing multiple treatment delays secondary to adverse events may receive their individual maximally tolerated dose while dogs with no adverse events may be underdosed. Future studies should focus on individual patient dose optimization.
机译:业已证明,剂量密集型CHOP方案可改善非霍奇金淋巴瘤患者的预后,但目前对于犬淋巴瘤剂量密集型CHOP方案的评估尚有限。这项回顾性研究的假设是,与其他基于阿霉素的多药方案相比,为期15周的剂量密集型CHOP方案可缩短治疗时间,且疗效相似。用15周的CHOP化疗方案治疗了31位客户拥有的多中心淋巴瘤犬,总缓解率为100%,中位无进展间隔(PFI)为140天[95%置信区间(CI)91- 335天]。在多变量分析中,治疗延迟两次或更多次的狗的PFI和总体生存期显着延长。剂量强度与患者预后无关。经历不良事件继发多次治疗延迟的狗可能会接受其最大耐受剂量,而没有不良事件的狗则可能剂量不足。未来的研究应侧重于个别患者的剂量优化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号